%0 Journal Article
%A Khoja, Lilah
%A Weber, Rachel Palmieri
%A Webb, Penelope M
%A Jordan, Susan J
%A Muthukumar, Aruna
%A Chang-Claude, Jenny
%A Fortner, Renée T
%A Jensen, Allan
%A Kjaer, Susanne K
%A Risch, Harvey
%A Doherty, Jennifer Anne
%A Harris, Holly R
%A Goodman, Marc T
%A Modugno, Francesmary
%A Moysich, Kirsten
%A Berchuck, Andrew
%A Schildkraut, Joellen M
%A Cramer, Daniel
%A Terry, Kathryn L
%A Anton-Culver, Hoda
%A Ziogas, Argyrios
%A Phung, Minh Tung
%A Hanley, Gillian E
%A Wu, Anna H
%A Mukherjee, Bhramar
%A McLean, Karen
%A Cho, Kathleen
%A Pike, Malcolm C
%A Pearce, Celeste Leigh
%A Lee, Alice W
%T Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
%J Gynecologic oncology
%V 164
%N 1
%@ 0090-8258
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2021-02557
%P 195-201
%D 2022
%Z 2022 Jan;164(1):195-201
%X To evaluate the association between hysterectomy and ovarian cancer, and to understand how hormone therapy (HT) use and endometriosis affect this association.We conducted a pooled analysis of self-reported data from 11 case-control studies in the Ovarian Cancer Association Consortium (OCAC). Women with (n = 5350) and without ovarian cancer (n = 7544) who never used HT or exclusively used either estrogen-only therapy (ET) or estrogen+progestin therapy (EPT) were included. Risk of invasive epithelial ovarian cancer adjusted for duration of ET and EPT use and stratified on history of endometriosis was determined using odds ratios (ORs) with 95
%K Endometriosis (Other)
%K Hormone therapy (Other)
%K Hysterectomy (Other)
%K Ovarian cancer (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34776242
%R 10.1016/j.ygyno.2021.10.088
%U https://inrepo02.dkfz.de/record/177465